Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML - Results from Study AML-BFM 2004
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10294960" target="_blank" >RIV/00216208:11130/15:10294960 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/15:10294960
Result on the web
<a href="http://dx.doi.org/10.1055/s-0035-1548816" target="_blank" >http://dx.doi.org/10.1055/s-0035-1548816</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1055/s-0035-1548816" target="_blank" >10.1055/s-0035-1548816</a>
Alternative languages
Result language
angličtina
Original language name
Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML - Results from Study AML-BFM 2004
Original language description
Background: The outcome in children and adolescents with high-risk (HR) acute myeloid leukemia (AML) is still unsatisfactory. Therefore, in study AML-BFM 2004 we aimed to improve outcome of HR-patients by adding moderately dosed 2-Chloro-2-Deoxyadenosine(2-CDA) to the respective consolidation treatment backbone without increasing toxicity. The aim was to improve prognosis especially in FAB M4/M5/MLL patients, who represent the largest subgroup of HR patients. Patients and Methods: In total, 343 children and adolescents with HR-AML were randomized to receive or not 2-CDA (6 mg/m(2)/d, days 1, 3) in combination with cytarabine/idarubicine (AI = 500 mg/m(2) cytarabine 5 days continuous infusion plus 7 mg/m(2)/d idarubicin, days 3 and 5). Results: Resultsfor patients of the AI/2-CDA arm (n = 168) vs. the AI-arm (n = 175) were similar: 5-year overall survival 68 +/- 4 vs. 72 +/- 4 %, p(logrank) = 0.38, event-free survival 53 +/- 4 vs. 49 +/- 4 %, p(logrank) = 0.77; cumulative incidence of
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Klinische Padiatrie
ISSN
0300-8630
e-ISSN
—
Volume of the periodical
227
Issue of the periodical within the volume
3
Country of publishing house
DE - GERMANY
Number of pages
7
Pages from-to
116-122
UT code for WoS article
000354653100003
EID of the result in the Scopus database
2-s2.0-84929587307